Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Czech | Egypt | Finland | France | Germany | Greece | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Luxembourg | Malaysia | Mexico | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Edmond Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Chronic Obstructive Pulmonary Disease|Skin Diseases, Genetic|Bronchiectasis
Phase 3: Chronic Obstructive Pulmonary Disease
Phase 2: Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12624001381572 | P4 |
Not yet recruiting |
Bronchiectasis |
2025-07-17 |
|
BETTER | P4 |
Recruiting |
Bronchiectasis |
2024-09-13 |
|
REPEAT Study | P4 |
Completed |
Skin Diseases, Genetic |
2023-04-04 |
|
ChiCTR2100054291 | N/A |
Recruiting |
Healthy Volunteers |
2022-01-31 |